• 🌎 Worldwide
    • 🇺🇸 U.S.
    • 🇨🇦 Canada
    • 🇬🇧 United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Investments Marijuana Stocks

GW Pharma Reports Fiscal First Quarter 2018 Financials

D.M.O. Newswire by D.M.O. Newswire
August 7, 2018
in Marijuana Stocks, Press Releases, United States
GW Pharmaceuticals Plc (NASDAQ: GWPH) Cannabis Stock News
133
SHARES
ShareShare

London, U.K. — August 7, 2018 — /D.M.O. Newswire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the first quarter ended 31 December 2017.

“With the Epidiolex regulatory applications accepted for review in both the US and Europe, and an assigned mid-year FDA decision date, 2018 is expected to be an exciting year for our Company with an anticipated first U.S. approval and launch. The commercial teams are making great progress toward launching Epidiolex with full conviction,” stated Justin Gover, GW’s Chief Executive Officer. “We also continue to see a significant flow of clinical data from the Epidiolex program through both medical meetings such as the American Epilepsy Society and in publication including our recent Lennox-Gastaut syndrome results in The Lancet. Beyond Epidiolex, we expect to progress a number of important pipeline programs during 2018 that have the potential to offer additional value.”

OPERATIONAL HIGHLIGHTS

  • Epidiolex (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and infantile spasms (IS)
    • Regulatory:
    • NDA for the adjunctive treatment of seizures associated with LGS and Dravet syndrome accepted for priority review with planned PDUFA goal date of June 27, 2018
    • European submission accepted for review by the EMA.  Expected decision in Q1 2019
    • Clinical data:
    • First Phase 3 LGS trial published in The Lancet
       • Second Phase 3 LGS trial publication anticipated in H1 2018
    • Clinical trials
    • Phase 3 trial in Tuberous Sclerosis Complex ongoing with data expected H2 2018
    • Second Phase 3 trial in Dravet syndrome enrollment complete with data expected H2 2018
    • Part A of two-part Phase 2/3 trial in Infantile Spasms underway
    • Manufacturing
    • FDA GMP inspections scheduled
    • Expanded access program and open label extension:
    • Over 2,000 patients now have been exposed to Epidiolex treatment
    • 97 percent of patients who complete Phase 3 trials have entered long term extension
    • Commercial:
    • Head of U.S. Sales appointed, completing the full U.S. commercial leadership team
    • Active discussions in U.S. with a wide variety of payors and insurance programs
    • EU commercial footprint now in place in five major European markets
    • Life-cycle management
    • Several new formulations of CBD in development including modified liquid formulations, a solid dose form and an intravenous formulation
    • Intellectual property
    • Several patent applications related to the use of CBD in certain forms of epilepsy being prosecuted with expected Track One decisions in Q2 2018
    • Additional patent applications being filed as new data is generated
  • Pipeline progress
    • CBDV in epilepsy
    • Data from CBDV Phase 2 partial-onset epilepsy study in adults expected in Q1 2018
    • CBDV in Autism Spectrum Disorders
    • 10-patient investigator-initiated expanded access program for seizures associated with autism underway
    • Investigator-led 100 patient placebo-controlled trial in autism spectrum disorder due to commence in Q2 2018
    • Open label study in Rett syndrome due to commence in Q2 2018 and Phase 2 placebo-controlled trial in Rett syndrome due to commence in Q3 2018
    • Orphan Drug Designation from FDA for CBDV for the treatment of Rett syndrome
    • Sativex®  (nabiximols)
    • US development and commercialization rights reacquired – plans underway to commence US pivotal trial in MS spasticity
    • CBD:THC in Glioblastoma
    • Pivotal clinical development program plans under development
    • Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD program
    • Phase 1 trial complete
    • Orphan Drug and Fast Track Designations granted from FDA and EMA
  • Board appointments
    • Three new independent members appointed to Board of Directors.

FINANCIAL HIGHLIGHTS

  • Revenue for the three months ended 31 December 2017 of £5.7 million ($7.7 million) compared to £2.1 million for the three months ended 31 December 2016.
  • Loss for the three months ended 31 December 2017 of £47.0 million ($63.3 million) compared to £15.6 million for the three months ended 31 December 2016.
  • Cash and cash equivalents at 31 December 2017 of £414.8 million ($559.2 million) compared to £241.2 million as at 30 September 2017.

Solely for the convenience of the reader, the above balances have been translated into U.S. dollars at the rate on 31 December 2017 of $1.3482 to £1. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as at that or any other date.

Conference Call and Webcast Information
GW Pharmaceuticals will host a conference call and webcast to discuss the first quarter 2018 financial results today at 4:30 pm EST. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company’s website at http://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-481-4010 or 919-882-2331 (international). For both dial-in numbers please use conference ID # 13675963 and PIN: 24706.

About GW Pharmaceuticals plc and Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted an NDA to the FDA and an MAA with the EMA for the adjunctive treatment of LGS and Dravet syndrome. The Company continues to evaluate Epidiolex in additional epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for gliobastoma, schizophrenia and epilepsy. For further information, please visit http://www.gwpharm.com.

Forward-looking statements

This news release contains forward-looking statements that reflect GW’s current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Sativex and Epidiolex and the safety profile and commercial potential of Sativex and Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission including the most recent Form 20-F filed on 4 December 2017. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Enquiries:

GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations 401 500 6570
 

Sam Brown (U.S. Media Enquiries)

 
Mike Beyer 312 961 2502
EU Media Enquiries:
FTI Consulting
 
Ben Atwell +44 (0) 203 727 1000
GW Pharmaceuticals plc
Condensed consolidated income statement
Three months ended 31 December 2017 and 2016
Three months
ended
Three months
 ended
Three months
ended
31 December
31 December
31 December
2017
2017
2016
$000’s
£000’s
£000’s
Revenue
7,728
5,732
2,056
Cost of sales
(1,190
)
(883
)
(715
)
Research and development expenditure
(40,818
)
(30,276
)
(24,914
)
Sales, general and administrative expenses
(23,445
)
(17,390
)
(6,684
)
Net foreign exchange (loss)/gain
(3,442
)
(2,553
)
11,815
Operating loss
(61,167
)
(45,370
)
(18,442
)
Interest expense
(320
)
(237
)
(90
)
Interest and other income
1,621
1,202
273
Loss before tax
(59,866
)
(44,405
)
(18,259
)
Tax (expense)/benefit
(3,433
)
(2,546
)
2,663
Loss for the period
(63,299
)
(46,951
)
(15,596
)
 
 
Loss per share – basic and diluted
(20.3c)
(15.0p)
(5.2p)
Loss per ADS – basic and diluted(1)
(243.6c)
(180.0p)
(62.4p)
 
 
Weighted average ordinary shares outstanding (in millions) – basic and diluted
312.1
302.7

All activities relate to continuing operations.
(1) Each ADS represents 12 ordinary shares.

Condensed consolidated statement of comprehensive loss
Three months ended 31 December 2017 and 2016

Three months
ended
31 December
2017
£000’s
Three months
ended
31 December
2016
£000’s
Loss for the period
(46,951
)
(15,596
)
Items that may be reclassified subsequently to profit or loss
Exchange (loss)/gain on retranslation of foreign operations
(187
)
418
Other comprehensive (loss)/gain for the period
(187
)
418
Total comprehensive loss for the period
(47,138
)
(15,178
)

 

GW Pharmaceuticals plc
Condensed consolidated statement of changes in equity
Three months ended 31 December 2017 and 2016
 
  Share
 
Share
  premium
  Other
Accumulated
 
capital
  account
  reserves
  deficit
  Total
 
£000’s
£000’s
£000’s
£000’s
£000’s
Balance at 1 October 2016
302
556,477
19,538
(177,827
)
398,490
Exercise of share options
2
88
–
–
90
Share-based payment transactions
–
–
–
2,166
2,166
Loss for the period
–
–
–
(15,596
)
(15,596
)
Deferred tax attributable to unrealized share option gains
–
–
–
(255
)
(255
)
Other comprehensive income
–
–
418
–
418
Balance at 31 December 2016
304
556,565
19,956
(191,512
)
385,313
 
 
Balance at 1 October 2017
304
556,570
18,822
(297,521
)
278,175
Issue of share capital
33
223,037
–
–
223,070
Expenses of new equity issue
–
(903
)
–
–
(903
)
Share-based payment transactions
–
–
–
4,127
4,127
Loss for the period
–
–
–
(46,951
)
(46,951
)
Deferred tax attributable to unrealized share option gains
–
–
–
469
469
Other comprehensive expense
–
–
(187
)
–
(187
)
Balance at 31 December 2017
337
778,704
18,635
(339,876
)
457,800

 

GW Pharmaceuticals plc
Condensed consolidated balance sheets
As at 31 December 2017 and 30 September 2017
 
As at
31 December
As at
31 December
As at
30 September
2017
  2017
2017
Non-current assets
$000’s
£000’s
 £000’s
Intangible assets – goodwill
7,024
5,210
5,210
Other intangible assets
2,258
1,675
1,049
Property, plant and equipment
62,117
46,074
43,666
Deferred tax asset
10,508
7,794
6,282
81,907
60,753
56,207
Current assets
 
Inventories
5,344
3,964
4,244
Taxation recoverable
27,838
20,648
20,072
Trade receivables and other current assets
18,222
13,516
11,217
Cash and cash equivalents
559,227
414,795
241,175
 
610,631
452,923
276,708
Total assets
692,538
513,676
332,915
Current liabilities
 
Trade and other payables
(45,895
)
(34,042
)
(33,119
)
Current tax liabilities
(6,017
)
(4,463
)
(838
)
Obligations under finance leases
(280
)
(208
)
(205
)
Deferred revenue
(1,195
)
(886
)
(2,307
)
 
(53,387
)
(39,599
)
(36,469
)
 
Non-current liabilities
 
Trade and other payables
(13,199
)
(9,790
)
(9,256
)
Obligations under finance leases
(6,341
)
(4,703
)
(4,755
)
Deferred revenue
(2,405
)
(1,784
)
(4,260
)
Total liabilities
(75,332
)
(55,876
)
(54,740
)
Net assets
617,206
457,800
278,175
 
Equity
 
Share capital
454
337
304
Share premium
1,049,849
778,704
556,570
Other reserves
25,124
18,635
18,822
Accumulated deficit
(458,221
)
(339,876
)
(297,521
)
Total equity
617,206
457,800
278,175

 

GW Pharmaceuticals plc
Condensed consolidated cash flow statements
For the three months ended 31 December 2017 and 2016
 
Three months
ended
Three months
ended
Three months
ended
31 December
31 December
31 December
  2017
  2017
  2016
$000’s
  £000’s
£000’s
Loss for the period
(63,299
)
(46,951
)
(15,596
)
Adjustments for:
 
Interest expense
320
237
90
Interest and other income
(1,621
)
(1,202
)
(273
)
Tax expense/(benefit)
3,433
2,546
(2,663
)
Depreciation of property, plant and equipment
2,069
1,535
1,059
Impairment of property, plant and equipment
–
–
95
Amortization of intangible assets
127
94
18
Net foreign exchange losses/(gains)
3,442
2,553
(11,815
)
Increase in provision for inventories
36
27
28
Decrease in deferred signature fees
(3,716
)
(2,756
)
(429
)
Share-based payment charge
5,564
4,127
2,166
Loss on disposal of property, plant and equipment
5
4
557
(53,640
)
(39,786
)
(26,763
)
Decrease/(increase) in inventories
341
253
(416
)
Increase in trade receivables and other current assets
(465
)
(345
)
(1,974
)
Increase in trade and other payables and deferred revenue
219
162
5,613
Income taxes paid
–
–
(450
)
Research and development tax credits received
232
172
–
Net cash outflow from operating activities
(53,313
)
(39,544
)
(23,990
)
Investing activities
 
Interest received
684
507
138
Purchases of property, plant and equipment
(8,785
)
(6,516
)
(1,376
)
Purchases of intangible assets
(562
)
(417
)
(220
)
Net cash outflow from investing activities
(8,663
)
(6,426
)
(1,458
)
Financing activities
 
Proceeds on exercise of share options
–
–
90
Proceeds of new equity issue
300,743
223,070
–
Expenses of new equity issue
(425
)
(315
)
(134
)
Interest paid
(320
)
(237
)
(247
)
Repayments of fit out funding
(127
)
(94
)
(564
)
Repayments of obligations under finance leases
(67
)
(50
)
(95
)
Net cash inflow/(outflow) from financing activities
299,804
222,374
(950
)
Effect of foreign exchange rate changes on cash and cash equivalents
(3,753
)
(2,784
)
12,253
Net increase/(decrease) in cash and cash equivalents
234,075
173,620
(14,145
)
Cash and cash equivalents at beginning of the period
325,152
241,175
374,392
Cash and cash equivalents at end of the period
559,227
414,795
360,247

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: GW Pharmaceuticals Plc.NASDAQ:GWPH

Get Real-Time Updates from MJobserver.com

Unsubscribe
D.M.O. Newswire

D.M.O. Newswire

D.M.O. Newswire is the cannabis industry's trusted news and press release dissemination service.

Related Posts

Epidiolex from GW Pharmaceuticals
Investments

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 3, 2021
Epidiolex from GW Pharmaceuticals
Investments

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

October 21, 2020
Epidiolex from GW Pharmaceuticals
Executives

GW Pharmaceuticals Announces the Appointment of David Gryska to its Board of Directors

September 10, 2020
Cannabis News - Marijuana Becomes Legal in Michigan Starting December 6th
Press Releases

GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity

June 4, 2020
Bank of America Merrill Lynch Marijuana Stock Research Coverage
Events

GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020

May 1, 2020
Epidiolex from GW Pharmaceuticals
Investments

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020

April 21, 2020
Load More
Next Post
Scythian Biosciences Corp. (TSXV:SCYB) (OTC:SCCYF) (FRA:9SB) Marijuana Stock Update

Scythian Biosciences Announces Licencing of Colcanna SAS to Cultivate and Import THC into Colombia

Leave a Comment! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

🚨 Subscribe to Stock Alerts

Get Live Updates on Breaking News

Subscribe Now

✉️ Subscribe to Our Newsletter!

* indicates required

🔎 Search Marijuana Stocks

📰 Recent News

  • J. Arnold Wealth Management Discloses New Stake in Cannabis ETF
  • Bank of America Increases its SNDL Holdings
  • The Lift & Co. Expo is back helping Canada build responsible, prosperous cannabis and psychedelics businesses
  • Bank of America Trims its Stake in Canopy Growth Corp.
  • Ballard Spahr Launches Cannabis Legislation Tracker to ID Industry Trends and Opportunities
Facebook Twitter Instagram LinkedIn Youtube

Cannabis News by Region

  • 🇺🇸 United States
  • 🇨🇦 Canada
  • 🇬🇧 United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Cannabis Tools & Resources

  • 📅 Calendar
  • 📊 Databases
  • 📇 Directories
  • 🔔 RSS Feeds
  • 📺 Videos

Find Cannabis Business Services

  • ⚖️ Attorneys & Law Firms
  • 📊 Accountants & Accounting Firms
  • 💡 Consultants & Consulting Firms
  • 📲 Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • 👀 Advertise
  • 📣 DMO Newswire
  • 📇 List in Our Databases

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • 🔒 PRO
    • 🔒 A.M. Watchlist
    • 🔒 Analyst Action
  • 💼 Business
  • 📈 Investments
    • 📈 Stocks
    • 💰 ETFs and Funds
    • 💭 Market Commentary
    • 📰 Press Releases
    • 📅 Earnings Calendar
  • ⚖️ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • 👥 People
    • ⚽ Athletes
    • 💼 Executives
    • 🌟 Celebrities
    • 🛒 Consumers
    • ⚕️ Doctors
    • 💊 Patients
  • 💊 Health
  • 📇 Databases
    • 📈 Stock Databases
    • 💰 Fund Databases
    • 💼 Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • 💲 Marijuana Cryptocurrencies

© 2018 - 2021 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observer™ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.